Bibliography
- Samii A, Nutt JG, Ransom BR. Parkinson's disease. Lancet 2004;363:1783-93
- Jankovic J. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 2008;79:368-76
- Shulman JM, De Jager PL, Feany MB. Parkinson's disease: genetics and pathogenesis. Annu Rev Pathol 2011;6:193-222
- Chiurchiu V, Maccarrone M. Chronic inflammatory diseases and their redox control: from molecular mechanisms to therapeutic opportunities. Antioxid Redox Signal 2011;5:2605-41
- Dyson SC, Barker RA. Cell-based therapies for Parkinson's disease. Expert Rev Neurother 2011;11:831-44
- Vidaltamayo R, Bargas J, Covarrubias L, Stem cell therapy for Parkinson's disease: a road map for a successful future. Stem Cells Dev 2010;19:311-20
- Lazic SE, Barker RA. Cell-based therapy for disorders of the CNS. Expert Opin Ther Patent 2005;15:1361-76
- Orlacchio A, Bernardi G, Orlacchio A, Martino S. Patented therapeutic RNAi strategies for neurodegenerative diseases of the CNS. Expert Opin Ther Patent 2008;18:1161-74
- Taupin P. Human neural progenitor and stem cells: US20080107633A1. Expert Opin Ther Patent 2009;19:377-80
- Drucker-Colin R, Verdugo-Diaz L. Cell transplantation for Parkinson's disease: present status. Cell Mol Neurobiol 2004;24:301-16
- Isacson O, Kordower JH. Future of cell and gene therapies for Parkinson's disease. Ann Neurol 2008;64:S122-38
- Freed CR, Greene PE, Breeze RE, Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 2001;344:710-19
- Kim HJ. Stem cell potential in Parkinson's disease and molecular factors for the generation of dopamine neurons. Biochim Biophys Acta 2011;1812:1-11
- Chung S, Leung A, Han BS, Wnt1-lmx1a forms a novel autoregulatory loop and controls midbrain dopaminergic differentiation synergistically with the SHH-FoxA2 pathway. Cell Stem Cell 2009;5:646-58
- Smidt MP, Burbach JP. How to make a mesodiencephalic dopaminergic neuron. Nat Rev Neurosci 2007;8:21-32
- Chung S, Moon JI, Leung A, ES cell-derived renewable and functional midbrain dopaminergic progenitors. Proc Natl Acad Sci USA 2011;108:9703-8
- Alves dos Santos MT, Smidt MP. En1 and Wnt signaling in midbrain dopaminergic neuronal development. Neural Dev 2011;6:23
- Sasaki H, Hui C, Nakafuku M, Kondoh H. A binding site for Gli proteins is essential for HNF-3beta floor plate enhancer activity in transgenics and can respond to Shh in vitro. Development 1997;124:1313-22
- Ono Y, Nakatani T, Sakamoto Y, Differences in neurogenic potential in floor plate cells along an anteroposterior location: midbrain dopaminergic neurons originate from mesencephalic floor plate cells. Development 2007;134:3213-25
- Kittappa R, Chang WW, Awatramani RB, McKay RD. The foxa2 gene controls the birth and spontaneous degeneration of dopamine neurons in old age. PLoS Biol 2007;5:e325
- The McLean Hospital Corporation. Compositions and methods for treatment of Parkinson's disease. WO2011/102847A1; 2011
- Carlsson T, Carta M, Winkler C, Serotonin neuron transplants exacerbate l-DOPA-induced dyskinesias in a rat model of Parkinson's disease. J Neurosci 2007;27:8011-22
- Carta M, Carlsson T, Kirik D, Bjorklund A. Dopamine released from 5-HT terminals is the cause of l-DOPA-induced dyskinesia in parkinsonian rats. Brain 2007;130:1819-33
- Maries E, Kordower JH, Chu Y, Focal not widespread grafts induce novel dyskinetic behavior in parkinsonian rats. Neurobiol Dis 2006;21:165-80
- Chung CY, Seo H, Sonntag KC, Cell type-specific gene expression of midbrain dopaminergic neurons reveals molecules involved in their vulnerability and protection. Hum Mol Genet 2005;14:1709-25
- Carrillo-Reid L, Tecuapetla F, Tapia D, Encoding network states by striatal cell assemblies. J Neurophysiol 2008;99:1435-50